Appointments at Catalent and Neuland – People on the move
Azopharma Product Development Group has appointed Daniel Cammarata as its chief financial officer (CFO). Cammarata has previously worked as CFO of AllianceCare and Interim Healthcare.
IGI Laboratories has appointed Hem Pandya as its CEO and president, effective June 29. Pandya replaces Rajiv Mathur who has resigned with immediate effect. Joyce Erony will be interim CEO in the transition period.
Pandya is currently CEO of NexMed and has previously worked at companies including Andrx Pharmaceuticals, Able Laboratories, Ivax Pharmaceuticals and Faulding/Purepac Pharmaceutical Company, which later became Alpharma.
In addition IGIhas named Bijoy Singh as its principal scientist, method development. The appointment gives Singh the option to purchase 25,000 shares of the IGI’s common stock.
Steve Leonard has been appointed as senior vice president of global operations at Catalent Pharma Solutions. Prior to joining Catalent Leonard worked for 22 years at GE Healthcare, most recently as general manager of global operationsof its medical diagnostics business.
Neuland Laboratories has promoted Sucheth Rao Davuluri to the position of CEO. Davuluri joined the company in 2002 and most recently served as vice president, operations and chief operating officer.
During his seven years at the India-based active pharmaceutical ingredient (API) supplier Davuluri has been involved in by expanding capacities and streamlining processes.
Oncotherapeutics has appointed David Donahue as its senior director of clinical operations. Prior to joining the contract research organisation (CRO) Donahue worked as director of clinical operations at Arena Pharmaceuticals.
Donahue has also worked at Qunitiles, FeRx and Syntex Research, now Roche Biosciences, for more than 10 years.
